CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed . . . Methods: This multicenter phase I II clinical trial (NCT03971799) was conducted as a 3+3 dose escalation study through the Pediatric Transplantation and Cell Therapy Consortium with National Marrow Donor Program sponsorship and managed by CIBMTR CRO
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR . . . Current CD33-targeted immunotherapies typically recognize the membrane-distal V-set domain of CD33 Here, we show that decreasing the distance between T cell and leukemia cell membrane increases the efficacy of CD33 chimeric antigen receptor (CAR) T cells
Developing a membrane-proximal CD33-targeting CAR T cell We developed a fully human-derived CAR T cell that targets the membrane-proximal IgC domain of CD33 (CD33-IgC) and improves preclinical CAR T cell efficacy compared with clinically validated lintuzumab-based CAR T cells targeting distal CD33 epitopes
702. CAR-T Cell Therapies: Basic and Translational Given the success of CD19 and CD22 chimeric antigen receptor (CAR) T cell immunotherapies for B-ALL, we developed and preclinically validated CD33-redirected CAR T cells (CD33CART; Qin JITC 2021) and translated a best-in-class CD33CART-CD28 CD3z product to the clinic
17MA030: CD33: CAR-T Cell Constructs that Recognize CD33 for the . . . CD33 is a transmembrane receptor of the SIGLEC family that is expressed on myeloid cells It is an effective target for treating AML as shown by in vivo AML mouse model studies where anti-CD33 CAR-T cells reduced leukemic burden and improved survival
Success of Centralized Manufacturing of CD33 CAR T-Cells (CD33CART) for . . . Early experience with CAR T-cell manufacturing in patients with AML has been challenging We describe feasibility of centralized manufacturing for CD33 CAR T-cell products (CD33CART) on the dose-escalation part of a multicenter Phase I II clinical trial in children and adolescents young adults (AYA) with r r AML (NCT03971799)